Drugs / 611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07042126 | Aug 2025 → Jun 2026 overdue | atopic eczema | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07042126 ↗ |
| Modality | Monoclonal antibody | “611 (Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody)” NCT07042126 ↗ |
| Route | Subcutaneous | “300 mg subcutaneous injection Q2W thereafter until week 16” NCT07042126 ↗ |